Quest Diagnostics Incorporated (NYSE:DGX) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET
Company Participants
Jim Davis - President & CEO
Sam Samad - EVP & CFO
Shawn Bevec - VP, IR
Conference Call Participants
Kevin Caliendo - UBS
Patrick Donnelley - Citi
Michael Cherny - Leerink Partners
Joanna Zhou - Evercore ISI
Pito Chickering - Deutsche Bank
David Westenberg - Piper Sandler
Andrew Brackmann - William Blair
Noah Kava - Jefferies
Jack Meehan - Nephron Research
Erin Wright - Morgan Stanley
Operator
Welcome to the Quest Diagnostics Fourth Quarter and Full-Year 2024 Conference Call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and the question-and-answer session that will follow, are the copyrighted property of Quest Diagnostics, with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics, is strictly prohibited.
I’d now like to introduce Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics. Sir, please go ahead.
Shawn Bevec
Thank you and good morning. I’m joined by Jim Davis, our Chairman, Chief Executive Officer and President, and Sam Samad, our Chief Financial Officer.
During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics’ future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long-term outlook